PubRank

Eduard F Stange

Author PubWeight™ 92.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006 5.10
2 Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005 5.05
3 Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010 2.88
4 NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004 2.47
5 Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 2011 2.31
6 A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002 2.15
7 Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003 2.06
8 NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2005 2.06
9 Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002 1.80
10 The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol 2007 1.73
11 Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006 1.73
12 Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003 1.72
13 Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002 1.59
14 Inflammatory Bowel Disease. Dtsch Arztebl Int 2016 1.56
15 Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007 1.48
16 Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology 2012 1.39
17 The expression patterns of peritoneal defensins. Perit Dial Int 2007 1.39
18 [Suspected cases of severe side effects after infliximab (Remicade) in Germany]. Med Klin (Munich) 2003 1.38
19 Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 2010 1.29
20 Paneth's disease. J Crohns Colitis 2010 1.29
21 Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005 1.27
22 Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 2004 1.26
23 Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol 2007 1.25
24 Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One 2009 1.24
25 Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006 1.21
26 Defensins and cathelicidins in gastrointestinal infections. Curr Opin Gastroenterol 2007 1.16
27 Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol 2007 1.14
28 Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo. PLoS One 2013 1.13
29 Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007 1.11
30 A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods 2005 1.05
31 Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes Infect 2009 1.03
32 Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. J Crohns Colitis 2011 1.03
33 Innate antimicrobial host defense in small intestinal Crohn's disease. Int J Med Microbiol 2009 0.96
34 Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J Lipid Res 2005 0.96
35 Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. J Lipid Res 2008 0.94
36 Paneth cells and the innate immune response. Curr Opin Gastroenterol 2006 0.91
37 Inflammatory bowel disease: an impaired barrier disease. Langenbecks Arch Surg 2012 0.91
38 Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn's disease. PLoS Genet 2012 0.88
39 Diminished expression of apical sodium-dependent bile acid transporter in gallstone disease is independent of ileal inflammation. Digestion 2008 0.88
40 More than a marine propeller--the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus. Int J Med Microbiol 2012 0.86
41 Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006 0.86
42 Human colonic mucus is a reservoir for antimicrobial peptides. J Crohns Colitis 2013 0.86
43 A new look at Crohn's disease: breakdown of the mucosal antibacterial defense. Ann N Y Acad Sci 2006 0.86
44 Human defensins in Crohn's disease. Chem Immunol Allergy 2005 0.86
45 Antimicrobial peptides in gastrointestinal inflammation. Int J Inflam 2010 0.86
46 Fatal staphylococcal sepsis in Crohn's disease after infliximab. Inflamm Bowel Dis 2004 0.85
47 Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression. Hum Genet 2009 0.85
48 Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 2004 0.85
49 Waking the wimp: redox-modulation activates human beta-defensin 1. Gut Microbes 2011 0.84
50 Symptomatic or asymptomatic gallstone disease: is the gallbladder motility the clue? Hepatogastroenterology 2002 0.84
51 Antimicrobial host defense in the upper gastrointestinal tract. Eur J Gastroenterol Hepatol 2008 0.83
52 A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease. PLoS One 2009 0.83
53 Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice. Biochem J 2002 0.81
54 Gastrointestinal involvement in granulomatosis with polyangiitis and microscopic polyangiitis: histological features and outcome. Int J Rheum Dis 2013 0.80
55 Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease. Expert Rev Anti Infect Ther 2007 0.80
56 Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease. Inflamm Bowel Dis 2005 0.80
57 Is there a role for defensins in IBD? Inflamm Bowel Dis 2008 0.80
58 Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice. Biochim Biophys Acta 2004 0.78
59 Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflamm Bowel Dis 2004 0.78
60 Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance. PLoS One 2013 0.78
61 Defective antibacterial barrier in inflammatory bowel disease. Dig Dis 2013 0.78
62 Antimicrobial peptides in the skin. N Engl J Med 2003 0.78
63 Innate antimicrobial immunity in inflammatory bowel diseases. Expert Rev Clin Immunol 2010 0.77
64 NOD2 mutation and mice: no Crohn's disease but many lessons to learn. Trends Mol Med 2005 0.77
65 Paneth cell function--implications in pediatric Crohn disease. Gut Microbes 2011 0.77
66 [Inflammatory bowel diseases--new therapeutic options]. Med Klin (Munich) 2008 0.76
67 Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflamm Bowel Dis 2013 0.76
68 [Clinical practice guideline on diagnosis and treatment of Crohn's disease - summary for the general practitioner]. Med Klin (Munich) 2009 0.76
69 Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease. BMC Gastroenterol 2013 0.76
70 Effects of SLC10A2 variant rs9514089 on gallstone risk and serum cholesterol levels- meta-analysis of three independent cohorts. BMC Med Genet 2011 0.76
71 Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease-the authors' response. Gut 2011 0.76
72 Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010 0.75
73 In Reply. Dtsch Arztebl Int 2016 0.75
74 How effective is natalizumab induction therapy in patients with Crohn's disease? Nat Clin Pract Gastroenterol Hepatol 2007 0.75
75 Antimicrobial activity of high-mobility-group box 2: a new function to a well-known protein. Antimicrob Agents Chemother 2013 0.75
76 For bugs in bile: the times they are a-changin'. Gastroenterology 2009 0.75
77 6-thioguanine-buried alive? Gastroenterology 2004 0.75
78 [Biological therapies for treatment of chronic inflammatory bowel diseases. Status update]. Med Klin (Munich) 2002 0.75
79 Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014 0.75
80 MALDI-TOF mass spectrometry screening of cholelithiasis risk markers in the gene of HNF1alpha. J Proteomics 2012 0.75
81 [Chronic inflammatory bowel diseases: psychological factors are not implicated]. Pflege Z 2004 0.75
82 Probiotics and intestinal diseases. Ann Nutr Metab 2010 0.75
83 Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument. Inflamm Bowel Dis 2003 0.75
84 Inflammatory bowel diseases. Preface. Dig Dis 2013 0.75